Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

13
Daiichi case: Delhi HC allows sale of Malvinder Singh’s shares

2018-05-14 livemint
New Delhi: The Delhi high court on Monday ordered the sale of unencumbered listed shares owned by former Ranbaxy promoter Malvinder Singh and others, in connection with the recovery of a Rs3,500 crore arbitration award in favour of Japanese drugmaker Daiichi Sankyo Co. Ltd.
AXBKY YESBANK AXBA FORTIS AXB AXISBANK OSCAR 501179 532648 YYBKY 532843 532215

3
Daiichi Sankyo case: Delhi HC orders sale of Shivinder Singh’s unencumbered listed shares

2018-05-08 livemint
New Delhi: The Delhi high court on Tuesday ordered the sale of unencumbered listed shares owned by former Ranbaxy promoter Shivinder Singh and others in connection with the recovery of a Rs3,500 crore arbitration award in favour of Japanese drugmaker Daiichi Sankyo Co. Ltd.
YESBANK OSCAR 501179 532648 YYBKY

1
Ranbaxy case: Delhi HC seeks details of exchange-listed shares held by Singh brothers

2018-04-25 livemint
New Delhi: The Delhi high court on Wednesday asked a court-appointed chartered accountant to submit a list of all exchange-listed unpledged shares held by former Ranbaxy promoters Malvinder Mohan Singh and Shivinder Mohan Singh and others in relation to the enforcement of a Rs3,500 crore arbitration case with Japanese drug maker Daiichi Sankyo Co. Ltd.
FORTIS OSCAR 501179 532843

1
HC asks Fortis’ reply in Daiichi Sankyo’s attempt to stop its sale to Manipal

2018-04-06 livemint
New Delhi: The Delhi high court on Thursday directed Fortis Healthcare Ltd to file its reply and affidavit in an application moved by Japanese drugmaker Daiichi Sankyo seeking to prevent the sale of Fortis Healthcare to Manipal Health Enterprises.
FORTIS OSCAR 501179 532843

0
Fortis Healthcare rises 5%; Delhi Court asks firm to respond on Daiichi#39;s plea to stall restructuring process

2018-04-06 moneycontrol
Fortis Healthcare share price gained more than 5 percent intraday Friday after the Delhi Court asked company to respond on Daiichi's plea to stall restructuring process.
FORTIS OSCAR 501179 532843

0
Delhi HC orders attachment of Singh brothers’ moveable assets

2018-03-23 livemint
New Delhi: The Delhi high court on Friday ordered the attachment of all moveable property disclosed in an affidavit by former Ranbaxy Laboratories promoters, brothers Malvinder Singh and Shivinder Singh, and others in relation to a Rs3,500 crore arbitration case with Japanese drug maker Daiichi Sankyo Co. Ltd.
OSCAR 501179

0
Daiichi arbitration case: Delhi High Court orders attachment of Singh brothers#39; declared assets

2018-03-23 moneycontrol
The Delhi High Court on Friday ordered attachment of all declared assets of Singh brothers in a case related to the enforcement of a foreign arbitration award of Rs 3,500 crore by Japanese drug maker Daiichi Sankyo, according to a CNBC-TV18 report.
OSCAR 501179

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...